natgillin/translations-raw huggingface dataset:
Any changes in insulin therapy should be made only under medical supervision. • The KwikPen is suitable for use with Becton, Dickinson and Company (BD) pen needles. • Be sure the needle is completely attached to the Pen before use. • Do not share your Pen or needles. • Keep these directions for future reference.
Vsakršna zamenjava vrste insulina mora potekati pod zdravniškim nadzorom. • KwikPen je primeren za uporabo z iglami za peresnik družbe Becton, Dickinson and Company (BD). • Pred uporabo se prepričajte, da je igla čvrsto pritrjena na Pen. • Svojega Pena ali igel ne delite z drugimi. • Navodila shranite, da jih boste lahko ponovno prebrali.
Frequently Asked Questions about Preparing the Pen
Pogosta vprašanja v zvezi s predpripravo Pena
• What should my insulin look like?
• Kako mora izgledati insulin?
• Why should I use a new needle for each injection?
• Zakaj moram za vsako injiciranje uporabiti novo iglo?
If needles are reused, you may get the wrong amount of insulin, a clogged needle, a jammed Pen, or an infection.
Če igle ponovno uporabite, boste morda prejeli napačen odmerek insulina, morda bo zamašena igla, Pen ali boste dobili okužbo.
313 Priming the Kwik Pen
322 Priprava KwikPena
• Prime every time.
• Injekcijski peresnik vsakič pripravite.
The Pen must be primed to a stream of insulin before each injection to make sure the Pen is ready to dose. • If you do not prime, you may get too much or too little insulin.
Pred vsakim injiciranjem morate Pen pripraviti do curka insulina, da zagotovite, da je Pen pripravljen za odmerjanje. • Če injekcijskega peresnika ne pripravite, lahko prejmete preveč ali premalo insulina.
• Why should I prime my Pen before each dose?
• Zakaj moram pred vsakim odmerjanjem pripraviti moj Pen?
Ensures that the Pen is ready to dose.
Za zagotovitev, da je Pen pripravljen za odmerjanje.
• What should I do if I cannot completely push in the Dose Knob when priming the Pen?
• Kaj moram storiti, če pri pripravi Pena gumba za odmerjanje ne morem pritisniti do konca?
Prime the Pen.
Pripraviti Pen.
• What should I do if I see an air bubble in the cartridge?
• Kaj moram storiti, če v vložku vidim zračni mehurček?
You need to prime the Pen.
Pen morate pripraviti.
Remember, do not store the Pen with the needle attached as this may cause air bubbles to collect in the insulin cartridge.
Zapomnite si, da Pena ne shranjujete s pritrjeno iglo, ker bi to lahko povzročilo nabiranje zračnih mehurčkov v vložku.
Injecting Your Dose
Pomembna opozorila
Important Notes • Follow the instructions for sanitary injection technique recommended by your healthcare professional. • Do not attempt to inject your insulin by turning the Dose Knob.
• Sledite navodilom za pravilne tehnike injiciranja, ki jih priporoča vaše zdravstveno osebje. • Insulina ne poskušajte injicirati z obračanjem gumba za odmerjanje.
You must PUSH the Dose Knob straight in for the dose to be delivered. • Do not attempt to change the dose while injecting. • The directions regarding needle handling are not intended to replace local, healthcare professional and/or institutional policies. • Remove the needle after completing each injection.
Da boste prejeli odmerek, morate gumb za odmerjanje PRITISNITI do konca. • Med injiciranjem ne poskušajte spreminjati odmerka. • Navodila glede ravnanja z iglami ne nadomeščajo lokalnih smernic, smernic zdravstvenega osebja in/ ali ustanov. • Iglo odstranite po vsakem končanem injiciranju.
• Why is it difficult to push the Dose Knob when I try to inject?
• Zakaj pri injiciranju težko pritisnem gumb za odmerjanje do konca?
If the Dose Knob continues to be difficult to push after following the steps above, you may need a new Pen.
Če je pritiskanje gumba za odmerjanje oteženo še po tem ko ste sledili gornjim korakom, morda potrebujete nov Pen.
• What should I do if my Pen is jammed?
• Kaj moram storiti, če je moj Pen zamašen?
Your Pen is jammed if it is difficult to inject a dose or dial a dose.
Vaš Pen je zamašen, če je oteženo injiciranje ali nastavitev odmerka.
314 • Why is insulin leaking from the needle after I finished my dose?
323 • Zakaj po končanem odmerjanju, insulin izteka iz igle?
For the next dose, push and hold the Dose Knob in and count slowly for 5 seconds before removing the needle.
Pri naslednjem injiciranju pritisnite in držite gumb za odmerjanje ter preden potegnete ven iglo, počasi štejte do 5 sekund.
• What should I do if my dose is dialed and the Dose Knob is accidentally pushed in without a needle attached?
• Kaj moram storiti, če je odmerek nastavljen in pomotoma pritisnjen gumb za odmerjanje brez pritrjene igle?
• What should I do if I dial a wrong dose (too high or too low)?
• Kaj moram storiti, če nastavim napačen odmerek (previsok ali prenizek)?
• What should I do if I see insulin leaking from the Pen needle while dialing the dose or correcting the dose?
• Kaj moram storiti, če medtem ko nastavljam ali popravljam odmerek vidim, da iz igle Pena izteka insulin?
Dial the Pen down to zero and prime the Pen again (see “Priming the Pen” steps 2 A-D).
Nastavite Pen nazaj na nič ter ponovno nastavite Pen (glejte “ Priprava Pena ” korake 2 A- D).
• What should I do if my full dose cannot be dialed?
• Kaj moram storiti, če ne morem nastaviti celotnega odmerka?
The Pen will not allow you to dial a dose greater than the number of insulin units remaining in the cartridge.
Pen vam ne bo omogočil nastavitev odmerka, ki je višji od števila preostalih enot insulina v vložku.
If a partial dose remains in the Pen you may either:
Če je v Penu ostal še del odmerka, si lahko:
Give the partial dose and then give the remaining dose using a new Pen. or 2.
Injicirate del odmerka, za preostali del odmerka pa uporabite nov Pen. ali 2.
Give the full dose with a new Pen.
Injicirate celotni odmerek iz novega Pena.
• Why can I not dial the dose to use the small amount of insulin that remains in my cartridge?
• Zakaj ne morem nastaviti odmerka, da bi uporabil majhno količino insulina, ki je ostala v mojem vložku?
The Pen is designed to deliver at least 300 units of insulin.
Pen je oblikovan tako, da omogoči uporabo najmanj 300 enot insulina.
The Pen design prevents the cartridge from being completely emptied because the small amount of insulin that remains cannot be delivered accurately.
Oblika Pena preprečuje popolno izpraznjenje vložka, ker ni možno natančno odmerjanje majhne količine insulina, ki je ostala.
• Before the first use store your Pen in a refrigerator (2°C – 8°C).
• Pred prvo uporabo shranjujte vaš Pen v hladilniku (2°C - 8°C).
Do not use a Pen if it has been frozen. • Keep your Pen in use at room temperature and away from heat and light. • Do not store the Pen with the needle attached.
Pena ne uporabite, če je bil zamrznjen. • Vaš Pen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi in stran od virov toplote in svetlobe. • Pena ne shranjujte s pritrjeno iglo.
If the needle is left on, insulin may leak from the Pen, insulin may dry inside the needle causing the needle to clog, or air bubbles may form in the cartridge. • Refer to the Information for the package leaflet for complete insulin storage instructions. • After first use the pen should not be used beyond the time specified in the insulin package leaflet. • Dispose of used needles in a puncture-resistant container or as directed by your healthcare professional. • Dispose of used Pens as instructed by your healthcare professional and without the needle attached. • Keep the Pen out of the reach of children.
Uporabljene igle zavrzite v vsebniku, ki je odporen proti vbodom ali kot vam je naročilo vaše zdravstveno osebje. • Uporabljene Pene zavrzite kot vam je priporočilo vaše zdravstveno osebje ter brez pritrjene igle. • Pen shranjujte nedosegljivo otrokom.
315 Getting Ready Make sure you have the following items:
324 Pripravite se Prepričajte se, da imate vse naslednje pripomočke:
New Pen Needle
Novo iglo za Pen
Pen Parts
Deli Pena
KwikPen, and Needle∗ Assembly ∗sold separately
Sestavljanje KwikPena in igel∗ (∗se prodajajo ločeno)
(Needles Not Included)
Deli igle za Pen Deli KwikPena (Igle niso priložene) Papirni pokrov
Paper Tab
Oznaka
KwikPen Parts
Oznaka odmerka
Dose
G o
Indicator Dose Knob Outer Needle Shield
Zunanji pokrovček igle
Inner Needle Shield
Notranji pokrovček igle
Pen cap Rubber seal
Pokrov Pena Gumijasta zaporka
Cartridge Holder
Držalo insulinskega vložka
Pen Body
Ohišje Pena
Dose Window
Okence odmerj
Routine Use Follow these instructions for each injection 1.
Vsakodnevna uporaba Za vsako injiciranje sledite naslednjim navodilom 1.
Preparing the KwikPen A.
Predpriprava KwikPena A.
Pull Pen Cap to remove.
Snemite pokrov Pena.
Be sure to check
Prepričajte se in preverite vaš insulin:
Gently roll the Pen ten times
Pen nežno desetkrat povaljajte med dlanmi in ga
Push capped needle straight onto the Pen.
Porinite iglo skupaj s pokrovčkom naravnost na Pen.
your insulin for: • Type • Expiration date • Appearance
• rok uporabnosti
and invert the Pen ten times.
obrnite.
The insulin should look evenly mixed.
ni čvrsto pritrjena.
Use an alcohol swab to wipe the rubber seal on the end of the Cartridge Holder.
zaporko na koncu
Screw needle on until secure.
držala insulinskega vložka.
316 2.
325 2.
Priming the KwikPen Caution:
Priprava KwikPena Opozorilo:
If you do not prime before each injection, you may get too much or too little insulin.
Če injekcijskega peresnika ne pripravite pred vsakim injiciranjem, lahko prejmete preveč ali premalo insulina.
D. • With needle pointed up, push Dose Knob in until it stops and 0 is seen in the Dose
ne vidite 0.
Pull off Outer Needle Shield.
• Držite gumb
Dial 2 Units by
Snemite notranji nastavite na 2 pokrovček igle in enoti. ga zavrzite.
Holder to collect air at top.
držalu insulinskega vložka, da se zrak zbere na vrhu.
Knob in and count slowly for 5 seconds.
za odmerjanje in počasi štejte do 5 sekund.
• Priming is complete when a stream of insulin appears from the needle tip. • If a stream of insulin does not appear, repeat priming steps 2B thru 2D.
• Priprava je zaključena, ko iz konice igle priteče curek insulina. • Če curek insulina ne priteče, ponovite korake priprave od 2B do 2D.
If you do not see a stream of insulin from the needle tip and dialing the Pen is more difficult, change the needle and prime the Pen.
Če na konici igle ne vidite curka insulina in je nastavitev Pena otežena, zamenjajte iglo ter pripravite Pen.
317 3.
326 3.
Injecting Your Dose A.
Injiciranje odmerka A.
Turn Dose Knob to the number of units you need to inject.
Obrnite gumb za odmerjanje do števila enot, ki jih morate
If you dial too many units, you can correct the dose by dialing
Vbodite igloo v kožo z uporabo tehnik injiciranja, ki jih
Insert needle into skin using injection technique recommended by your healthcare professional.
Da prejmete celotni odmerek, držite gumb za odmerjanje pritisnjen in počasi
To deliver the full dose, hold Dose Knob in and count slowly for 5 seconds.
štejte do 5 sekund.
Remove needle from skin.
nastavite preveč
Carefully replace the Outer Needle Shield.
Iglo izvlecite iz kože.
Unscrew the capped needle and throw away as directed by your healthcare professional.
Liha
backwards.
Opomba:
The odd numbers are shown as full lines between the even numbers.
števila so prikazana kot cele črte med sodimi števili.
Place your thumb on the Dose Knob and push firmly until the Dose Knob stops moving.
čvrsto pritisnite gumb za odmerjanje do konca.
Check to make sure you see 0 in the Dose Window to confirm you received the complete dose.
odmerek, preverite, da se prepričate, da v okencu za odmerjanje vidite 0.
Remove the needle after each injection to keep air out of the cartridge.
odstranite iglo, da preprečite vstop zraka v vložek.
Do not store the Pen with the needle attached.
Pena ne shranjujte s pritrjeno iglo.
Replace Pen Cap.
Namestite nazaj pokrov Pena.
Example:
omogočil
10 units shown.
prikazanih je 10
The Pen will not allow you to dial more than the number of units left in the Pen.
nastaviti več, kot je
You may use this function to determine the total amount of insulin remaining in the Pen when the cartridge has less than 60 units remaining.
To lastnost lahko uporabite enot. za določitev celotne količine insulina, ki je ostala v Penu potem, ko je v vložku ostalo manj kot 60 enot.
15 units shown.
Če je vaš odmerek višji od števila preostalih enot v Penu, lahko uporabite količino, ki je ostala v vašem Penu, ki ga Primer: trenutno uporabljate in nato uporabite prikazanih je 15 nov Pen, da dobite celoten odmerek ALI enot. za celotni odmerek uporabite nov Pen.
318
327
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali s farmacevtom.
Humira is a medicine containing the active substance adalimumab.
Humira je zdravilo, ki vsebuje zdravilno učinkovino adalimumab.
It is available as a solution for injection in a vial, pre-filled syringe or pre-filled pen, all containing 40 mg adalimumab.
Na voljo je kot raztopina za injiciranje v viali, napolnjeni injekcijski brizgi ali napolnjenem injekcijskem peresniku, vse oblike pa vsebujejo po 40 mg adalimumaba.
Humira is an anti-inflammatory medicine.
Zdravilo Humira je protivnetno zdravilo.
It is used to treat the following groups of patients: • adults with moderate to severe active rheumatoid arthritis (an immune system disease causing inflammation of the joints) who have not responded adequately to other treatments, and adults with severe active rheumatoid arthritis that is progressive (getting worse) who have not taken methotrexate (another medicine that acts on the immune system) before.
Uporablja se pri zdravljenju naslednjih skupin bolnikov: • pri odraslih bolnikih z zmernim do hudim aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov), ki se ne odzivajo zadostno na druge oblike zdravljenj, ter pri odraslih s progresivnim (napredujočim) hudim aktivnim revmatoidnim artritisom, ki prej še niso dobivali metotreksata (še eno zdravilo, ki vpliva na imunski sistem).
Humira is used in combination with methotrexate, or on its own in patients who cannot take methotrexate; • adolescents aged between 13 and 17 years with polyarticular juvenile idiopathic arthritis (an immune system disease affecting children and adolescents that causes inflammation of at least five joints) who have not responded adequately to other treatments.
Zdravilo Humira se uporablja v kombinaciji z metotreksatom ali samostojno pri bolnikih, ki ne prenašajo metotreksata; • pri mladostnikih od 13 do 17 leta s poliartikularnim idiopatskim juvenilnim artritisom (boleznijo imunskega sistema, ki pri otrocih in mladostnikih povzroča vnetje najmanj petih sklepov), ki se ne odzivajo zadostno na druge oblike zdravljenja.
Humira is used in combination with methotrexate, or on its own in patients who cannot take methotrexate; • adults with active and progressive psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) who have not responded adequately to other treatments; • adults with severe active ankylosing spondylitis (a disease causing inflammation and pain in the joints of the spine) who have not responded adequately to other treatments; • adults with severe active Crohn’ s disease (a disease causing inflammation of the gut) who have not responded adequately to other treatments; • adults with psoriasis (a disease causing red, scaly patches on the skin) who have not responded adequately to other treatments.
Zdravilo Humira se uporablja v kombinaciji z metotreksatom ali samostojno pri bolnikih, ki ne prenašajo metotreksata; • pri odraslih z aktivnim in progresivnim psoriatičnim artritisom (boleznijo, ki povzroča nastajanje rdečih in luskinastih zaplat na koži in vnetje sklepov), ki se ne odzivajo zadostno na druge oblike zdravljenja; • pri odraslih s hudim aktivnim ankilozirajočim spondilitisom (boleznijo, ki povzroča vnetje in bolečine sklepov hrbtenice), ki se ne odzivajo zadostno na druge oblike zdravljenja; • pri odraslih s hudo aktivno Crohnovo boleznijo (boleznijo, ki povzroča vnetje prebavil), ki se ne odzivajo zadostno na druge oblike zdravljenja; • pri odraslih s psoriazo (boleznijo, ki povzroča rdeče, luskinaste zaplate na koži), ki se ne odzivajo zadostno na druge oblike zdravljenja.
See the Summary of Product Characteristics (also part of the EPAR) for full details.
Za več informacij si oglejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Treatment with Humira must be initiated and supervised by a doctor who has experience in the treatment of the diseases that Humira is used to treat.
Zdravljenje z zdravilom Humira mora uvesti in nadzirati zdravnik z izkušnjami z zdravljenjem bolezni, ki se zdravijo s tem zdravilom.
Patients who need a more rapid response for Crohn’ s disease may need to start with two higher doses 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Priporočeni odmerek zdravila Humira znaša 40 mg in se daje vsaka dva tedna v obliki ene same podkožne injekcije, vendar začetni odmerek pri Crohnovi bolezni in 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged psoriazi znaša 80 mg, kateremu sledi 40- miligramski odmerek vsaka dva tedna.
(160 mg followed by 80 mg), although this might increase the risk of side effects.
Za bolnike, pri katerih je potreben hitrejši odziv na zdravljenje Crohnove bolezni, bo morda potrebno podvojiti prva dva odmerka (160 mg, ki mu sledi 80- miligramski odmerek), čeprav se lahko pri tem poveča tveganje pojava neželenih učinkov.
Patients may be given other medicines during treatment with Humira, such as corticosteroids (other anti-inflammatory medicines).
Med zdravljenjem z zdravilom Humira se lahko bolnikom dajejo tudi druga zdravila, kot so kortikosteroidi (druga protivnetna zdravila).
After training, patients may inject themselves with Humira if their doctor agrees.
Ob soglasju zdravnika si lahko bolniki po opravljenem usposabljanju sami vbrizgavajo zdravilo Humira.
Patients who take Humira must be given the special alert card that summarises the safety information about the medicine.
Bolniki, ki prejemajo zdravilo Humira, morajo dobiti posebno opozorilno izkaznico, ki povzema varnostne podatke o zdravilu.
The active substance in Humira, adalimumab, is a monoclonal antibody.
Zdravilna učinkovina adalimumab v zdravilu Humira je monoklonsko protitelo.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
Monoklonsko protitelo je vrsta protitelesa (vrsta beljakovine), ki je bilo zasnovano za prepoznavanje in vezanje na točno določeno strukturo (imenovano antigen) na določenih celicah telesa.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Humira is used to treat.
Ta obveščevalna molekula sodeluje pri vnetjih in je prisotna v visokih koncentracijah pri bolnikih, ki jih zdravijo z zdravilom Humira.
By blocking TNF, adalimumab reduces the inflammation and other symptoms of the diseases.
Z zaviranjem TNF učinkovina adalimumab zmanjša vnetje in druge simptome bolezni.
Humira has been studied in five studies of patients with moderate to severe rheumatoid arthritis.
Zdravilo Humira so raziskovali v petih študijah z zmernim do hudim revmatoidnim artritisom.
In four of these studies, the effectiveness of Humira, alone or as an as add-on to other anti-inflammatory medicines including methotrexate, was compared with that of placebo (a dummy treatment) in over 2,000 patients.
V štirih od teh študij so učinkovitost zdravila Humira, ki so ga dajali samostojno ali kot dodatek zdravljenju z drugim protivnetnim zdravilom, vključno z metotreksatom, primerjali z učinkom placeba (zdravilom brez zdravilne učinkovine) pri več kot 2000 bolnikih.
The fifth study compared the combination of Humira and methotrexate to methotrexate or to Humira alone in 799 patients who had not taken methotrexate before.
Peta študija je vključevala 799 bolnikov, ki v preteklosti še niso prejemali metotreksata, v njej pa so kombinacijo zdravila Humira in metotreksata primerjali s samostojnim dajanjem metotreksata ali zdravila Humira.
For polyarticular juvenile idiopathic arthritis, Humira was compared with placebo, alone or as an add- on to methotrexate, in one main study involving 171 patients aged between four and 17 years.
V eni glavnih študij je bilo vključenih 171 bolnikov, starih od 4 do 17 let, s poliartikularnim juvenilnim idiopatskim artritisom, primerjali pa so učinek zdravila Humira in placeba, ki so ga dajali samostojno ali kot dodatek metotreksatu.
All of the patients received Humira for 16 weeks before being assigned to Humira or placebo for a further 32 weeks.
Vsi bolniki so prvih 16 tednov prejemali zdravilo Humira, naslednjih 32 tednov pa so prejemali ali zdravilo Humira ali placebo.
For psoriatic arthritis, Humira was compared with placebo over 12 weeks in two studies including 413 patients.
V dveh študijah, ki sta vključevali 413 bolnikov s psoriatičnim artritisom, so zdravilo Humira primerjali s placebom.
The medicines were taken alone or in combination with another anti-inflammatory medicine.
Zdravili so dajali samostojno ali v kombinaciji z drugim protivnetnim zdravilom.
For ankylosing spondylitis, Humira and placebo as an add-on to existing treatment were compared over 12 weeks in two studies involving 397 patients.
V dveh študijah, ki sta vključevali 397 bolnikov z ankilozirajočim spondilitisom, so primerjali zdravilo Humira in placebo, ki so ju uporabili kot dodatka že obstoječemu zdravljenju.
For Crohn’ s disease, the effectiveness of the first two doses of Humira (induction) was compared with that of placebo in two studies involving 624 patients over four weeks.
V dveh študijah, ki sta vključevali 624 bolnikov s Crohnovo boleznijo, so v 4 tednih zdravljenja primerjali učinkovitost prvih dveh odmerkov zdravila Humira (indukcija) s placebom.
Another study looked at the long-term effects (maintenance) of Humira in 854 patients over up to 56 weeks.
Druga študija je proučevala dolgotrajne učinke (vzdrževanje) zdravila Humira pri 854 bolnikih v obdobju 56 tednov.
For psoriasis, Humira was compared with placebo over 16 weeks in 1,212 patients.
Pri psoriazi so učinke zdravila Humira v 16 tednih primerjali z učinki placeba pri 1212 bolnikih.
In all of the studies, the main measure of effectiveness was the change in symptoms.
Glavno merilo učinkovitosti v vseh študijah je bila sprememba simptomov.
Humira was more effective than placebo in all diseases studied.
Zdravilo Humira je bilo učinkovitejše od placeba v vseh študijah bolezni.
In rheumatoid arthritis, the greatest reductions in symptoms were seen in the studies examining Humira as an add-on to methotrexate: around two thirds of the patients adding Humira had at least a 20% reduction in symptoms after six months, compared with a quarter of those adding placebo.
V primeru revmatoidnega artritisa so največja zmanjšanja simptomov opazili v študijah, v katerih so raziskovali zdravilo Humira kot dodatek zdravljenju z metotreksatom: po šestih mesecih sta približno dve tretjini bolnikov, ki so kot dodatno zdravljenje prejemali zdravilo Humira, pokazali 20- odstotno zmanjšanje jakosti simptomov, v primerjavi s četrtino tistih bolnikov, ki so kot dodatek prejemali placebo.
Patients adding Humira also had less joint damage and experienced less reduction in physical function after a year.
Bolniki, ki so zdravilo Humira prejemali kot dodatno zdravljenje, so po enem letu zdravljenja pokazali tudi manjši obseg poškodb sklepov in so bili bolj telesno zmožni kot tisti, ki so prejemali placebo.
In patients who had not taken methotrexate in the past, the combination of Humira and methotrexate was also more effective than methotrexate alone.
Pri bolnikih, ki predhodno še niso prejemali metotreksata, je bila kombinacija zdravila Humira in metotreksata prav tako učinkovitejša od samostojnega jemanja metotreksata.